Wockhardt Wins U.S. FDA Approval For Zithromax Generic
This article was originally published in PharmAsia News
Mumbai-based Wockhardt plans soon to launch its generic version of Pfizer's infection-treatment drug Zithromax (azitromycin) in the United States after being cleared by the FDA for marketing. Wockhardt was the first of four generics makers to win FDA clearance. The firm's chairman said the win was a reflection of the Wockhardt's strong research and development for bulk drugs and formulations. (Click here for more
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.